Search results
Author(s):
Yvonne Millerick
,
Jayne Masters
,
Charlie Bloe
,
et al
Start date:
Dec 29, 2020
View more
Author(s):
Koji Hasegawa
,
Masayuki Yoshida
Added:
6 years ago
This video was supplied by the International Society of Cardiovascular Pharmacotherapy (ISCP) and discusesCardiovascular risk management of diabetes and SGLT2 inhibitors
Lecturer: Masayuki Yoshida, Professor of Medicine, Tokyo Medical and Dental University, Japan
Interviewer: Koji Hasegawa, Leader, Cardiovascular Clinical Research Network, National Hospital Organization,Shizuoka, Japan
View more
Author(s):
Ramy Doss
,
Chiadi Ndumele
Added:
4 months ago
AHA 2023 — CardioNerds Ambassador, Dr Ramy Doss (Nazareth Hospital, US) is joined by Dr Chiadi E Ndumele (Johns Hopkins University, US) to talk about AHA's Presidential Advisory on Cardiovascular-Kidney-Metabolic Health (CKM).The presidential advisory focuses on the cardiovascular-kidney-metabolic (CKM) syndrome, a systemic disorder connecting heart disease, kidney disease, diabetes and obesity…
View more
Author(s):
Chris Wai Hang Lo
,
Yue Fei
,
Bernard Man Yung Cheung
Added:
3 years ago
Author(s):
Ferdinando Iellamo
,
Karl Werdan
,
Krzysztof Narkiewicz
,
et al
Added:
3 years ago
Cardiovascular disease (CVD) is the leading cause of death worldwide and it is predicted that its incidence will increase markedly, particularly in developed countries, despite the introduction of new drugs and devices. One of the factors accounting for the limited effectiveness of pharmacological therapy is poor adherence to treatment, particularly in elderly patients. The use of combinations of…
View more
Author(s):
Ramón Luengo-Fernández
Added:
7 months ago
ESC 2023 — Dr Ramón Luengo-Fernández (University of Oxford, UK) joins us on-site to discuss the findings from a registry which aimed to analyse the economic burden of cardiovascular disease within the EU.
This was the first study to utilise Europe-wide patient registries and included the costs of long-term social care. Results from the registry found that cardiovascular disease cost the EU €282…
View more
Author(s):
Mark A Peterzan
,
Oliver J Rider
,
Lisa J Anderson
Added:
3 years ago
Heart failure (HF) can be defined haemodynamically as any abnormality of cardiac structure or function resulting in a failure to deliver oxygen at a rate adequate for tissue requirements, despite normal filling pressures – or only at the expense of increased filling pressures.1 Around half of patients with HF have reduced left ventricle ejection fraction (LVEF; EF <40 %) at rest (HF-REF).2
…
View more
Author(s):
Ernest Spitzer
,
Ben Ren
,
Jasper J Brugts
,
et al
Added:
3 years ago
The coronavirus disease 2019 (COVID-19) pandemic started in Wuhan, Hubei Province, China, in December 2019, and by 24 April 2020, it had affected >2.73 million people in 185 countries and caused >192,000 deaths.1 The pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was believed to have reached humans through a zoonotic infection.2 SARS-CoV-2 is the third coronavirus…
View more
Author(s):
Perry Elliott
Added:
7 years ago
Perry Elliot discusses "Genetic markers in cardiovascular disease: any major advance in everyday practice?" at the 2016 ESC Congress in Rome, Italy.
View more
Author(s):
Robert D Adam
,
James Shambrook
,
Andrew S Flett
Added:
3 years ago
The current lifetime risk of heart failure is approximately one in three and the prognosis remains poor.1 The latest UK heart failure audit data reveal inpatient and 1-year mortality rates of 10% and 27%, respectively.2
The aetiology of heart failure is diverse, and many patients have several cardiac and non-cardiac pathologies that conspire to cause the syndrome. Currently the most common cause…
View more